MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico

• Main Authors: Aurelio Cruz-Valdez (Author), Gabriel Valdez-Zapata (Author), Sanjay S. Patel (Author), Flavia V. Castelli (Author), Marcia G. Garcia (Author), Wim T. Jansen (Author), Ashwani Kumar Arora (Author), Esther Heijnen (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The poor immune response elicited by trivalent influenza vaccines (TIVs) in children can be enhanced by the addition of adjuvants. This observer-blind, randomized Phase III trial assessed the immunogenicity and safety of the MF59-adjuvanted trivalent influenza vaccine FLUAD® (aTIV) and a non-adjuvan...